Sara M. Tolaney, MD, MPH, discusses new data from the ASCENT-04 trial and their implications for community oncologists.

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.

Panelist discusses how efficacy and safety data from trials like ELEVATE-TN and CLL14 inform treatment decisions, noting that while both regimens are effective, patients with 17p deletion tend to ...

Panelist discusses how the SEQUOIA study demonstrated that zanubrutinib monotherapy maintains excellent progression-free survival in patients with high-risk chronic lymphocytic leukemia with TP53 ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS study using HLA-mismatched unrelated donors for peripheral blood and bone ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...